A Phase 3 interventional study of Ribociclib and Mono-chemotherapy in Breast Cancer, sponsored by Swiss Cancer Institute. Terminated at 35 sites in 3 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-16.
Sponsored by Swiss Cancer Institute · Phase 3, Interventional, and Treatment
The aim of this trial is to assess if patients treated with the combination of ribociclib and endocrine therapy respond to treatment as fast as patients treated with chemotherapy only, without decreasing their quality of life (QoL).
Breast cancer is the most frequent malignancy in women and the leading cause of cancer mortality in most countries in Europe. Metastatic breast cancer remains an incurable disease with a median overall survival (OS) of 2-4 years and a 5-year survival of only 25%. Patients with hormone receptor (HR)-positive breast cancer involving visceral disease at diagnosis have an even worse outcome.
Many oncologists still prefer to treat visceral disease primarily with chemotherapy rather than with endocrine treatment, thinking to receive a faster response with chemotherapy than with endocrine therapy, especially in patients with clinical symptoms or potentially threatening lesions. However, results from cross-sectional clinical practice studies suggest that endocrine therapy is associated with better quality of life, fewer concerns about side effects, less activity impairment and higher treatment satisfaction compared to chemotherapy. In addition, with the new data of CDK4/6 inhibitors combined with endocrine treatment there is an even better efficacy data available compared to endocrine therapy alone.
The aim of this trial is to assess if patients treated with the combination of ribociclib and endocrine therapy respond to treatment as fast as patients treated with chemotherapy only, without decreasing their quality of life (QoL).
12,815 studies on the registry are indexed under Breast Neoplasms; 2,920 are open to participants now.
This study's enrollment of 25 is below the median of 72 across 9,494 interventional studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Swiss Cancer Institute is the lead sponsor of 27 studies on the registry; 12 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with asymptomatic and stable (treated or untreated) central nervous system (CNS) metastases are eligible, provided they meet the following criteria:
Exclusion Criteria:
Drug: Ribociclib · Other: Endocrine-Therapy
Other: Mono-chemotherapy
Ribociclib 600mg p.o. d1-21, q4w in combination with endocrine treatment for 3 years.
mono-chemotherapy for at least 12 weeks (afterwards, maintenance endocrine therapy ± ribociclib inhibitor is allowed) and up to 3 years.
The choice of endocrine therapy is up to the investigator, but the chosen endocrine therapy has to be registered to be used in combination with ribociclib in the investigated indication.
Quality of life-adjusted early disease control
A patient will be counted as a success for this endpoint when during the first 12 weeks \- the response according to RECIST v1.1 is stable disease or better.
Time frame: at 12 weeks.
Quality of life-adjusted early disease control
A patient will be counted as a success for this endpoint when during the first 12 weeks \- the QoL according Functional Assessment of Cancer Therapy-Breast Trial Outcome Index \[FACT-B TOI\] score does not worsen by 5 points or more.
Time frame: at 12 weeks.
Disease Control (DC) at 12 weeks
A patient will be counted as a success for this endpoint when during the first 12 weeks the response according to RECIST v1.1 is stable disease or better. Patients with missing response assessments within the first 12 weeks will be counted as failure unless there was no progressive disease (PD) documented within the first 12 weeks and the first subsequent assessment also shows no PD
Time frame: week 6, 12.
Objective response rate (ORR)
ORR is defined as the proportion of patients having achieved complete response (CR) or partial response (PR) during trial treatment. Response will be evaluated according to RECIST v1.1 criteria.
Time frame: week 6, 12, then every 12 weeks up to 3 years or end of trial treatment.
Time to objective response (OR)
Time to OR will be calculated from randomization until first documented CR or PR according to RECIST v1.1 criteria. Time to OR will be calculated for patients having achieved a CR or PR at any time during trial treatment.
Time frame: week 6, 12, then every 12 weeks up to 3 years or end of trial treatment.
Progression-free survival (PFS)
PFS is defined as the time from randomization until progression according the RECIST v1.1 criteria or death from any cause, whichever occurs first. Patients not having an event at the time of analysis as well as patients starting a new anti-cancer therapy in the absence of an event will be censored at the date of their last tumor assessment before starting a new anti-cancer treatment, if any.
Time frame: week 6, 12, then every 12 weeks up to 3 years.
Time to treatment failure (TTF)
TTF is defined as the time from randomization until stopping of trial treatment from any cause. Patients not having an event at the time of analysis will be censored at the date of their last known date of trial treatment.
Time frame: week 6, 12, then every 12 weeks up to 3 years.
Overall survival (OS) at 3 years
OS at 3 years is determined by the Kaplan-Meier estimator for OS at 3 years. OS is defined as time from randomization to death due to any cause. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive.
Time frame: week 6, 12, then every 12 weeks up to 3 years.
Changes in overall QoL (FACT-B) until 24 months
Changes in Functional Assessment of Cancer Therapy-Breast (FACT-B) total score (score range 0-148, higher scores indicate better quality of life)
Time frame: Changes from baseline to 24 months
Time to QoL deterioration
Time to QoL deterioration is defined as the duration between baseline and first occurrence of a decrease of ≥ 5 points in the FACT-TOI score.
Time frame: From baseline to 24 months
Time to QoL improvement
Time to QoL improvement is defined as the duration between baseline and first occurrence of an increase of ≥ 5 points in the FACT-TOI score.
Time frame: From baseline to 24 months
Time to pain improvement
Improvements in pain will be assessed up to 24 months by the item pain severity of the Brief Pain Inventory (BPI), scale range: 0= no pain to 10 = pain as bad as one can imagine.
Time frame: From baseline to 24 months
Adverse events (AEs)
All AEs will be assessed according to NCI CTCAE v5.0.
Time frame: every 4 weeks up to 3 years.
This study is terminated, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ribociclib
Swiss Cancer Institute